16
Presentation to Cowen Healthcare Conference March 9, 2011 06/06/22

UniLife Corporation (NASDAQ: UNIS) @ Cowan

Embed Size (px)

DESCRIPTION

UniLife Corporation (NASDAQ: UNIS)Summary of Presentation by CEO Alan Shortall at 31st Annual Cowen & Company Healthcare Conference in Boston

Citation preview

Page 1: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Presentation to Cowen

Healthcare Conference

March 9, 201104/08/23

Page 2: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However you should not place undue reliance on any such forward looking statements as these are subject to risks and uncertainties.  Please refer to our press release and our SEC filings for more information regarding the use of forward looking statements.

204/08/23

Page 3: UniLife Corporation (NASDAQ: UNIS) @ Cowan

3

Introducing Unilife

Markets moving to mandatory safety

Best-in-class safety syringe portfolio

1st product line already FDA-cleared

Only prefilled with integrated safety

$40m agreement with sanofi-aventis

Discussions accelerating with other pharmaceutical companies

State-of-the-art facilities in PA

World-class Board / management

04/08/23

Emerging Global Leader for Innovative Drug Injection Devices

Page 4: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Unilife’s Operational Capabilities

165,000sqf state-of-the-art production facility in York, PA

Meets stringent pharma standards for primary drug containers

Eleven clean rooms, and other advanced infrastructure

Automated assembly systems used to attain optimal quality

Capacity to produce up to 400m units per year (stage 1)

404/08/23

Page 5: UniLife Corporation (NASDAQ: UNIS) @ Cowan

The Global Transition to Safety Syringes

Healthcare and pharmaceutical markets being driven by legislation to mandatory use of safety syringes

Needlestick injury reports not declining despite enforcement

Market preference for devices with passive, integrated safety

504/08/23

Page 6: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Delivery devices increasingly used as brand differentiator

Pharmaceutical Challenges for Prefilled Safety

2.4 billion prefilled syringes

Market growing 12% pa

50+ drugs / vaccines now in a prefilled syringe format

Only clip-on safety options available for compliance

Extra fill-finish process steps

Up to 70% more volume

Similar look / functionality

Standard prefilled syringe (left) next to three attached with an ancillary safety product

604/08/23

Unifill

Page 7: UniLife Corporation (NASDAQ: UNIS) @ Cowan

7

Unilife Technology

Core Proprietary Features

Fully integrated safety features

Automatic needle retraction

Eliminates needlestick risk

Operator controlled withdrawal

Directly from body into barrel

No risk of aerosol (splatter)

Non-reusable / tamper-proof

Intuitive use, convenient disposal

04/08/23

Page 8: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Developing a Full Proprietary Portfolio

Unifill® Ready-to-Fill syringes (glass barrel filled by pharma)

Commercial release 2011

Development Pipeline

Development Pipeline

Development Pipeline

Approved and launched

Development Pipeline

Staked needle (Subcutaneous)

Attachable needle (IM)

3, 5mL - used with standard luer needles

Staked needle (Insulin / TB)

ProjectTaipan

Project Liger

Unifill syringe

Unifill Select

Unitract 1mL

Unitract Clinical

Confidential Projects

Unitract® Clinical syringes(for use with vials)

804/08/23

Page 9: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Primary injectable drug container

Only prefilled syringe with safety integrated inside the glass barrel

USP-compliant materials

Integration into fill-finish systems

Minimal packaging, transport and storage volumes

Compact handling, intuitive use

Optimal protection from harm

The Unifill® Ready-to-Fill Syringe

904/08/23

Page 10: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Unifill preferred across all 5 areas:

Functionality

Safety

Appearance

Ease-of-use

Performance

Independent evaluations with 66 experienced U.S. nurses

Compared to leading prefilled ancillary safety products

Results of Independent Market Evaluations

1004/08/23

Page 11: UniLife Corporation (NASDAQ: UNIS) @ Cowan

11

Unique drug delivery device – not a commodity

Streamlines filling, packaging, transport and storage systems

Highest levels of protection for healthcare workers or patients

Patent protection up to 2030

Offers strong brand differentiation in competitive drug classes

Can help optimize or extend product lifecycles

Potential to obstruct generic or biosimilar competition

Unique Selling Proposition for Unifill

04/08/23

Page 12: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Potential Drug Candidates for Unifill Syringe

83 approved and pipeline drugs from 19 pharmaceutical companies across more than 20 therapeutic classes now available or potentially suitable for use in a prefilled syringe designated for subcutaneous injections

1204/08/23

Page 13: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Relationship with sanofi-aventis

Contributed approximately $40m for exclusive right to negotiate purchase of Unifill syringe until June 2014

Parties agreed to a Unifill syringe exclusivity list in March 2010

Thrombotics, vaccines and four other new pre-filled areas

Ten year exclusivity extension per drug class if commercial supply orders placed before 2014

Unilife required to commit only 30% of capacity

Other sub-classes may be added (agreement both parties)

1304/08/23

Page 14: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Other Pharmaceutical Discussions

1404/08/23

Initial Discussions Signed CDA

Request Samples for Validation

Collaboration / Development Agreement

Supply Agreements

Sanofi-aventis

Pharma 2

Pharma 3

Pharma 4

Pharma 5

Pharma 6

Pharma 7

Pharma 8

Pharma 9

Pharma 10

Pharma 11

Pharma 12

Pharma 13

Pharma 14

Pharma 15

Pharma 16

Pharma 17

Pharma 18

Pharma 19

Pharma 20

Page 15: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Preparing for Production and Sales

Qualified components ready – internal testing successful

A dozen experienced suppliers already qualified

Initial production to commence in late-March 2011

First assembly line to have 60 million unit / year capacity

Additional lines to have 150 million unit / year capacity

Initial sales to customers in mid-2011

Used for drug stability testing and market evaluations

1504/08/23

Page 16: UniLife Corporation (NASDAQ: UNIS) @ Cowan

Summary

1604/08/23

Markets driven by legislation to mandatory safety syringe use

Full portfolio of syringes with best-in-class safety features

World’s only prefilled syringes with safety inside glass barrel

$40 million from sanofi-aventis for exclusivity in defined classes

Accelerating talks with many other pharmaceutical leaders

State-of-the art production capabilities to meet demand

Highly experienced team with deep industry expertise

Significant projected revenue growth and attractive margins

2011 focus on production, sales and agreements